Abbott Laboratories (NYSE:ABT) Shares Unloaded Rep. Julia Letlow

Representative Julia Letlow (R-Louisiana) recently sold shares of Abbott Laboratories (NYSE:ABT). In a filing disclosed on January 13th, the Representative disclosed that they had sold between $1,001 and $15,000 in Abbott Laboratories stock on December 8th. The trade occurred in the Representative’s “MERRILL LYNCH INVESTMENT ACCOUNT #025” account.

Representative Julia Letlow also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Salesforce (NYSE:CRM) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Pinterest (NYSE:PINS) on 12/16/2025.
• Purchased $1,001 – $15,000 in shares of United Rentals (NYSE:URI) on 12/16/2025.
• Sold $1,001 – $15,000 in shares of Mettler-Toledo International (NYSE:MTD) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Icon Energy (NASDAQ:ICON) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Devon Energy (NYSE:DVN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of AstraZeneca (NASDAQ:AZN) on 12/8/2025.
• Purchased $1,001 – $15,000 in shares of Waters (NYSE:WAT) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of AbbVie (NYSE:ABBV) on 12/8/2025.
• Sold $1,001 – $15,000 in shares of Warner Bros. Discovery (NASDAQ:WBD) on 12/8/2025.

Abbott Laboratories Stock Performance

Shares of ABT stock opened at $124.90 on Thursday. The company has a quick ratio of 1.24, a current ratio of 1.70 and a debt-to-equity ratio of 0.23. The business has a 50 day moving average of $126.12 and a two-hundred day moving average of $129.14. The company has a market cap of $217.18 billion, a P/E ratio of 15.65, a PEG ratio of 2.06 and a beta of 0.72. Abbott Laboratories has a 52 week low of $110.86 and a 52 week high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Wednesday, October 15th. The healthcare product maker reported $1.30 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.30. The company had revenue of $11.37 billion during the quarter, compared to analyst estimates of $11.40 billion. Abbott Laboratories had a return on equity of 17.60% and a net margin of 31.88%.The firm’s quarterly revenue was up 6.9% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.21 EPS. As a group, analysts anticipate that Abbott Laboratories will post 5.14 EPS for the current year.

Abbott Laboratories Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, February 13th. Shareholders of record on Thursday, January 15th will be paid a dividend of $0.63 per share. The ex-dividend date is Thursday, January 15th. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.59. This represents a $2.52 annualized dividend and a yield of 2.0%. Abbott Laboratories’s payout ratio is presently 29.57%.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in ABT. IMG Wealth Management Inc. lifted its holdings in shares of Abbott Laboratories by 759.1% during the second quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock worth $26,000 after purchasing an additional 167 shares during the period. Cloud Capital Management LLC bought a new position in shares of Abbott Laboratories during the 3rd quarter worth approximately $29,000. Guerra Advisors Inc bought a new position in shares of Abbott Laboratories in the third quarter valued at approximately $31,000. Anfield Capital Management LLC increased its position in shares of Abbott Laboratories by 81.3% during the 2nd quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares during the last quarter. Finally, Delos Wealth Advisors LLC bought a new stake in shares of Abbott Laboratories in the 2nd quarter worth approximately $32,000. 75.18% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on ABT. The Goldman Sachs Group upped their price target on Abbott Laboratories from $153.00 to $157.00 and gave the company a “buy” rating in a research report on Wednesday, October 1st. Royal Bank Of Canada reiterated an “outperform” rating and set a $147.00 price target on shares of Abbott Laboratories in a research note on Thursday, October 16th. BTIG Research reaffirmed a “buy” rating and set a $145.00 price objective on shares of Abbott Laboratories in a research note on Thursday, November 20th. Wells Fargo & Company upped their price objective on Abbott Laboratories from $142.00 to $146.00 and gave the stock an “overweight” rating in a report on Thursday, October 16th. Finally, Daiwa Capital Markets upped their target price on shares of Abbott Laboratories from $134.00 to $136.00 and gave the company an “outperform” rating in a research note on Tuesday, October 21st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $147.68.

About Representative Letlow

Julia Letlow (Republican Party) is a member of the U.S. House, representing Louisiana’s 5th Congressional District. She assumed office on April 14, 2021. Her current term ends on January 3, 2027.

Letlow (Republican Party) is running for re-election to the U.S. House to represent Louisiana’s 5th Congressional District. She declared candidacy for the primary scheduled on November 3, 2026.

Julia Letlow earned a doctorate. Letlow’s career experience includes working as a senior administrator with the University of Louisiana at Monroe.

Abbott Laboratories Company Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.